Pelvic organ prolapse surgery after native tissue vault suspension at hysterectomy-A prospective cohort study.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 15 11 2018
revised: 18 06 2019
accepted: 21 06 2019
pubmed: 10 7 2019
medline: 6 2 2020
entrez: 9 7 2019
Statut: ppublish

Résumé

The effect of prophylactic vaginal vault suspension during hysterectomy in prevention of subsequent development of pelvic organ prolapse (POP) is unknown. We aimed to investigate incidences and risk of POP surgery in women who had undergone hysterectomy on benign indication with and without prophylactic suspension. We linked the national clinical Danish Hysterectomy and Hysteroscopy Database (DHHD) to administrative registries to assess data on all total hysterectomies (1 May 2012 to 31 December 2014), suspension methods, age, POP surgery, births, obstetric complications, prescriptions, socioeconomic- and vital status. Women undergoing total hysterectomy on non-prolapse and benign indication with no prior POP surgery were included and followed from hysterectomy to POP surgery, death/emigration or end of study period (maximum 2 years). Descriptive statistics, cumulative incidence curves and multivariable Cox proportional hazard models were fitted to assess the associated risk of POP in relation to prophylactic suspension. We included 7625 patients undergoing total hysterectomy; of these, 6538 (85.7%) were registered with prophylactic suspension during hysterectomy and 1087 (14.3%) women were specifically registered with no suspension in the DHHD. At baseline, women undergoing hysterectomy with suspension were on average 47.1 years of age (standard error SE 0.1) compared to 48.4 years (SE 0.3) in women with no suspension (p-value <0.0001). Moreover, women with suspension differed from their counterparts with no suspension with respect to geographical site of hysterectomy, hysterectomy method, parity and income. The cumulative risk of POP surgery after two years follow-up was 0.9% and 0.5% in the suspension group and the no suspension group, respectively. In the adjusted analysis, we found no association of prophylactic suspension and risk of POP surgery, hazard ratio (HR) = 2.1 (95% confidence interval (CI) 0.8-5.3, p-value 0.13). Of all women undergoing hysterectomy for benign indication, 0.84% (N = 64) were surgically treated for POP. At two-year follow-up, there was no association between prophylactic vaginal vault suspension at time of hysterectomy and subsequent POP surgery.

Identifiants

pubmed: 31284088
pii: S0301-2115(19)30314-8
doi: 10.1016/j.ejogrb.2019.06.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-150

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Lisbeth Bonde (L)

Department of Obstetrics and Gynecology, Nykoebing Falster Hospital, Nykoebing Falster, Denmark; University of Southern Denmark, Odense, Denmark. Electronic address: lisbeth.bonde@dadlnet.dk.

Lauge Østergaard (L)

Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.

Emil L Fosbøl (EL)

Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark.

Lars A Møller (LA)

Department of Obstetrics and Gynecology, Zealand University Hospital, Roskilde, Denmark.

Bent Ottesen (B)

Department of Gynecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Gunnar H Gislason (GH)

University of Southern Denmark, Odense, Denmark; Department of Cardiology, Herlev and Gentofte University Hospital, Herlev/Hellerup, The Danish Heart Foundation, Copenhagen, Denmark.

Helga Gimbel (H)

University of Southern Denmark, Odense, Denmark; Department of Obstetrics and Gynecology, Zealand University Hospital, Roskilde, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH